American Board of Pediatrics
BA, Cornell University
MD, University of Pennsylvania
Internship, Internal Medicine
New York Presbyterian Hospital
New York Presbyterian - Weill Cornell Medical Center
English, Italian, Spanish
As hypertension is the second highest cause of death, detecting a genetic basis would provide new treatment modalities and would serve as a significant public health measure. Microarray studies are being utilized to study three newly discovered diseases whose genetic basis is unknown: a) Familial Hyperaldosteronism II; b) resistance to all steroids; c) a disorder of sexual differentiation in which a 46,XY SRY positive female (whose ovaries are also SRY positive) has given birth to a 46,XY female. After 50 years at Cornell, the Dr. New and her team moved to Mount Sinai in 2004, where the research in steroid disorders including clinical, hormonal and molecular studies has prospered.
The primary research emphasis is on genetic steroid disorders. We continue to study two monogenic disorders: 21-hydroxylase deficiency and-hydroxylase deficiency, emphasizing genotype/phenotype correlation and prenatal diagnosis and treatment. A more precise definition of salt-wasting Congenital Adrenal Hyperplasia owing to 21-hydroxylase deficiency is being developed, in which mineralocorticoid secretion is evaluated by salt-deprivation studies. For the first time, patients who were treated in fetal life are old enough to participate in long-term outcome studies.
These studies will establish the safety of prenatal treatment, as they will include medical and psychoendocrine (gender) evaluations. We have made worldwide collaborations to study mutations in the CYP21A2 gene and have preliminary data indicating that mutations have ethnic specificity. Mice with a deletion of the CYP21A2 gene are being bred for studies and vectors are prepared for studies of gene therapy. As we have the largest population with Apparent Mineralocorticoid Excess (AME) owing to 11B-HSD2 deficiency, a disease Dr. New discovered in 1977, we are conducting medical follow-up searching for end organ disease. We have discovered a new mild form of AME, in which the phenotype is not as severe as the cases first described and the mutations in the 11B-HSD2 gene are different. This mild form may prove to be an important basis for low renin hypertension, which constitutes 40% of essential hypertension.
Nimkarn S, Lin-Su K, New MI, Wilson R, Berglind N. Aldosterone-to-Renin Ratio as a Marker for Disease Severity in 21-Hydroxylase Congenital Adrenal Hyperplasia. J Clin Endo Metab 2007 January; 92(1): 137-142.
Wilson RC, Nimkarn S, Dumic M, New MI, Azar M, Najmabadi H, Saffari F, Obeid J. Ethnic Specific Distribution of Mutations in 716 Patients with Congenital Adrenal Hyperplasia Owing to 21-Hydroxylase Deficiency. Mol Genet Metab 2007 Jan; E-Pub .
Trinh L, Lin-Su K, New MI, Nimkarn S. Growth and pubertal characteristics in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Ped Endocrinol Metab;.
New MI. Extensive Personal Experience: Nonclassical 21-Hydroxylase Deficiency. J Clin Endo Metab 2006; 91: 4222-4231.
Meyer-Bahlburg HL, Dolezal C, New MI, Kessler SJ, Schober JM, Zucker KJ. The Recalled Gender Questionnaire-Revised: A Psychometric Analysis in a Sample of Women with Congenital Adrenal Hyperplasia. J Sex Res 2006; 43(4): 364-367.
Bhangoo A, Ten S, New MI, Wilson R. Donor splice mutation in the 11β-hydroxylase (CYP11B1) gene resulting in sex reversal: a case report and review of the literature. J Pediatr Endrocinol Metab 2006; 19: 1267-1282.
Ergun-Longmire B, Auchus R, New MI, Tansil S, Wilson RC, Papri-Zareei M. Two novel mutations found in a patient with 17α-hydroxylase deficiency. J Clin Endocrinol Metab 2006; 91(10): 4179-4182.
Meyer-Bahlburg HF, Dolezal C, New MI, Ehrhardt AA, Baker SW. Gender Development in Women with Congenital Adrenal Hyperplasia as a Function of Disorder Severity. Arch Sex Behav 2006; 35: 667-684.
Ergun-Longmire B, Vinci G, Alonso L, New MI, Lin-Su K, McElreavey K, Tansil S. Clinical, hormonal and cytogenetic evaluation of 46,XX males and review of the literature. J Pediatr Endocrinol Metab 2005; 23(8): 739-748.
Lin-Su K, Vogiatzi MG, Marshall I, New MI, Macapagal MC, Betensky B, Tansil S, Harbison MD. Treatment with Growth Hormone and LHRH Analogue Improves Final Adult Height in Children with Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab 2005; 90: 3318-3325.
New MI, Wilson RC. Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess. . Proc Natl Acad Sci 1999.; 96:: 12790-12797.
Lin-Su K, Zhou P, Arora N, Betensky B, New MI, Wilson RC. In Vitro Expression Studies Of A Novel Mutation Δ299 In A Patient Affected With Apparent Mineralocorticoid Excess (AME). . J Clin Endocrinol Metab. 2004; 89: 2024-2027.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.New did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.